RAD51D Breast Cancer Mutation May Predict Chemo Response
A Yonsei Cancer Center team found that RAD51D-mutated breast cancer showed aggressive features but responded strongly to chemotherapy before surgery, suggesting a potential treatment-response marker.
This article was automatically drafted and passed editorial compliance checks. It synthesizes public source metadata and is not a substitute for individual care or clinical review.
Researchers Cho Sung-yeon, Park Hyung-seok and Park Ji-soo at Yonsei Cancer Center analyzed the characteristics of RAD51D-mutated breast cancer and its response to chemotherapy given before surgery. The team announced the results on August 27, 2026.
The team linked the mutation with aggressive tumor characteristics but also found a strong response to preoperative chemotherapy. The study suggests RAD51D status could help predict treatment response, and the findings were published in Molecular Therapy – Oncology.
What the study found
RAD51D participates in repairing damaged DNA, as do BRCA1 and BRCA2. The Yonsei Cancer Center team examined a question that had remained unclear: how a RAD51D mutation relates to breast cancer characteristics and treatment response.
The key result was a contrast: RAD51D-mutated breast cancer had aggressive features, yet it responded strongly to chemotherapy administered before surgery. The researchers therefore proposed RAD51D status as a possible clue for anticipating chemotherapy response.
Limits and clinical context
The three reports characterize RAD51D as a potential predictive marker, not a stand-alone treatment decision. Their summaries do not give response percentages, patient numbers, side effects, or recovery outcomes, so the result cannot determine what any one patient will experience.
A mutation-associated pattern in a study does not remove individual variation. A qualified cancer specialist should interpret genetic findings alongside the patient’s diagnosis and treatment plan, and patients should consult the care team about expected benefits, side effects and recovery considerations.
Questions for a consultation
Patients with a RAD51D result can ask what the finding means for their specific breast cancer and whether it is relevant to chemotherapy before surgery. They can also ask how the care team weighs the tumor’s aggressive features against the reported treatment-response pattern.
The consultation should cover how clinicians will monitor response and which side effects or recovery issues matter for the proposed plan. The study points to a possible predictive role for RAD51D, while the treating team must apply that information to the individual patient.
Frequently asked questions
Does a RAD51D mutation mean chemotherapy will work for me?
The Yonsei Cancer Center team found a strong response to chemotherapy before surgery among RAD51D-mutated breast cancers and proposed the mutation as a possible predictive marker. The result describes a research pattern, so a specialist must interpret it in light of individual variation and the patient’s diagnosis.
Is RAD51D-mutated breast cancer more aggressive?
The research team associated RAD51D-mutated breast cancer with aggressive characteristics. The same analysis also found a strong response to chemotherapy before surgery, so both findings belong in a discussion with the treating specialist.
Can a RAD51D result decide my treatment by itself?
The researchers presented RAD51D as a potential clue for predicting chemotherapy response. The reports support discussing the result with a qualified specialist, who can relate it to the individual diagnosis and treatment plan.
Questions to take to your cancer specialist
- What does my RAD51D result mean for my breast cancer diagnosis?
- Could this mutation inform whether chemotherapy before surgery is relevant to me?
- How will you assess and monitor my response to treatment?
- Which side effects and recovery considerations should we discuss for my plan?
- How does individual variation affect the interpretation of this research?
MediIndex articles are for general information only and are not medical advice, diagnosis, or advertising. Outcomes vary by individual — consult a board-certified specialist for personal decisions.
